Synaptogenix And Cleveland Clinic To Submit Investigational New Drug Application To FDA For Clinical Trial Of Bryostatin-1 In Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Synaptogenix and Cleveland Clinic are planning to submit an Investigational New Drug application to the FDA for a clinical trial of Bryostatin-1 in Multiple Sclerosis. The study aims to evaluate the drug's potential neuro-restorative mechanisms for improving synaptic health and cognitive function in MS patients.
July 19, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Synaptogenix's plans to submit an IND application to the FDA for Bryostatin-1 in MS could potentially boost the company's profile and stock value if the application is successful.
The news of Synaptogenix's plans to submit an IND application to the FDA for a clinical trial of Bryostatin-1 in MS is directly related to the company and its future prospects. If the application is successful, it could lead to a potential new treatment for MS, which would likely boost the company's profile and stock value. However, the outcome of the application is uncertain, hence the confidence score of 70.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100